HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: safe
Other drugs that affect hemostasis increase bleeding risk Can cause heparin-induced thrombocytopenia (HIT) and bleeding.
Heparin binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin (factor IIa) and other serine proteases (factors Xa, IXa, XIa, XIIa) in the coagulation cascade, thereby preventing fibrin clot formation.
| Metabolism | Primarily cleared by the reticuloendothelial system and metabolized in the liver via desulfation and depolymerization; partially renally excreted as unchanged drug. Metabolism is saturable and dose-dependent. |
| Excretion | Heparin is eliminated primarily via hepatic metabolism and renal excretion. Approximately 50% of a dose undergoes hepatic desulfation and depolymerization to form uroheparin, which is excreted in urine. Unchanged heparin is cleared renally via saturable, dose-dependent mechanisms. Biliary/fecal elimination is negligible (<5%). |
| Half-life | Terminal elimination half-life is 1-2 hours at therapeutic doses, dose-dependent: 30-60 min after IV bolus of 25 U/kg, increasing to 1.5-2.5 hours after 400 U/kg. Prolonged in hepatic/renal impairment and pulmonary embolism. Clinical context: continuous infusion achieves steady-state after ~4-6 hours. |
| Protein binding | High protein binding to antithrombin III (ATIII), albumin, and other proteins; overall ~95% bound. |
| Volume of Distribution | 0.05-0.07 L/kg (confined to plasma volume). Distribution is limited due to high protein binding and large molecular weight; does not cross placenta or blood-brain barrier. |
| Bioavailability | SC: ~30% (variable due to binding to endothelial cells and macrophages). IV: 100%. IM: not recommended. Oral: negligible (<1% due to GI degradation and large molecular size). |
| Onset of Action | Intravenous (IV): immediate (anticoagulation within 1-2 minutes). Subcutaneous (SC): delayed (20-30 minutes to peak effect). Not administered IM due to hematoma risk. |
| Duration of Action | IV bolus: 2-4 hours (dose-dependent). Continuous IV infusion: sustained effect. SC: 8-12 hours. Effects reversed within 2-4 hours after discontinuation. Protamine sulfate reverses within 5 minutes. |
| Molecular Weight | Average 15000 Da (range 6000-20000 Da) |
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; subsequent dose adjusted based on aPTT. Typical infusion rate: 20,000–40,000 units/24 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment required; monitor aPTT closely in renal impairment due to accumulation risk. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce dose by 25–50% and monitor aPTT frequently due to decreased anticoagulant factors. |
| Pediatric use | IV bolus: 75–100 units/kg; maintenance: 20 units/kg/hour continuous infusion; adjust to target aPTT (e.g., 60–85 seconds). Monitor closely. |
| Geriatric use | Initial bolus and infusion rates at lower end of range; consider 50 units/kg bolus and 15 units/kg/hour due to increased bleeding risk and reduced clearance. |
| 1st trimester | Heparin is the anticoagulant of choice in pregnancy due to its inability to cross the placenta. Animal studies and clinical experience have not shown fetal risk. |
| 2nd trimester | Same as first trimester. Heparin does not cross the placenta and is considered safe. Monitor for bleeding and osteoporosis with prolonged use. |
| 3rd trimester | Same as second trimester. May be used for thromboembolism prophylaxis or treatment. Avoid if active bleeding or imminent delivery due to hemorrhagic risk. |
Clinical note
Other drugs that affect hemostasis increase bleeding risk Can cause heparin-induced thrombocytopenia (HIT) and bleeding.
| FDA category | Human |
| Placental transfer | None. Heparin is highly charged and does not cross the placenta. |
■ FDA Black Box Warning
Spinal/epidural hematoma risk in patients receiving neuraxial anesthesia or spinal puncture: Use of anticoagulants, including heparin, increases risk of spinal or epidural hematoma resulting in long-term or permanent paralysis. Monitor for signs/symptoms of neurological impairment and treat urgently.
| Common Effects | bleeding |
| Serious Effects |
Active major bleedingThrombocytopenia (especially heparin-induced thrombocytopenia)Heparin hypersensitivitySevere uncontrolled hypertensionRecent surgery with high bleeding riskHemophilia or other bleeding diathesis
| Precautions | Hemorrhage: Major bleeding risk; monitor aPTT and adjust dose. Heparin-induced thrombocytopenia (HIT): Monitor platelet counts; discontinue if HIT suspected. Osteoporosis: Long-term use associated with bone loss. Hyperkalemia: Due to aldosterone suppression. Preservative-free formulation required for neonates/infants to avoid benzyl alcohol toxicity. |
Loading safety data…
| Breastfeeding |
| Heparin is not excreted into breast milk due to its high molecular weight and polarity, therefore it is considered safe during breastfeeding. No effects on the nursing infant are expected. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Heparin does not cross the placenta and is not associated with teratogenic effects. No increased risk of fetal malformations has been observed in any trimester. |
| Fetal Monitoring | Monitor maternal platelet counts for heparin-induced thrombocytopenia (HIT), signs of bleeding, and activated partial thromboplastin time (aPTT) to maintain therapeutic levels. Fetal monitoring is not required as heparin does not cross the placenta. |
| Fertility Effects | Heparin is not known to affect fertility in males or females. No reproductive toxicity has been reported. |
| Food/Dietary |
| No direct food interactions with heparin. However, avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if transitioning to warfarin, but this is not relevant during heparin infusion. |
| Clinical Pearls | HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER is a fixed-concentration heparin solution (125 units/mL) for continuous IV infusion. Dextrose 5% provides free water but minimal calories; monitor serum glucose in diabetics. Confirm patency of IV line and avoid simultaneous infusion with other drugs due to incompatibilities. Use a dedicated IV line. For weight-based dosing, standard concentration is often 100 units/mL; this 125 units/mL may require dose verification. Monitor aPTT every 6 hours initially and adjust infusion rate per nomogram. Do not use if solution is precipitate or colored. |
| Patient Advice | This medication is an anticoagulant that prevents blood clots. · You will receive this as a continuous infusion through an IV line. · Report any unusual bleeding, bruising, blood in urine or stool, or black/tarry stools immediately. · Avoid aspirin, NSAIDs (like ibuprofen), and other blood thinners unless prescribed by your doctor. · Do not take any new medications or supplements without consulting your healthcare provider. · You may need regular blood tests (aPTT) to monitor the effect of heparin. · Inform your healthcare providers (including dentists) that you are on heparin before any procedure. · Do not stop the infusion abruptly; it will be tapered as directed. |